| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Medicine |
Through Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein KinaseDependent Cyclooxygenase-2 Expression in MacrophagesFrom the Department of Metabolic Medicine (M.Y., T.M., T.S., N.I., Y.M., K.T., H.M., T.T., K.S., D.K., T.N., E.A.), Graduate School of Medical Sciences, Kumamoto University, Japan; Department of Physiology (Y.T.), Graduate School of Medicine, Kanazawa University, Japan; Laboratory of Nutrition Chemistry (T.K.), Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Japan; and Department of Medicine, Diabetes Research Center (M.B.), Albert Einstein College of Medicine, Bronx, NY.
Correspondence to Takeshi Matsumura, MD, PhD, Department of Metabolic Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Kumamoto 860-8556, Japan. E-mail takeshim{at}gpo.kumamoto-u.ac.jp
Both statins and peroxisome proliferator-activated receptor (PPAR)
ligands have been reported to protect against the progression of atherosclerosis. In the present study, we investigated the effects of statins on PPAR
activation in macrophages. Statins increased PPAR
activity, which was inhibited by mevalonate, farnesylpyrophosphate, or geranylgeranylpyrophosphate. Furthermore, a farnesyl transferase inhibitor and a geranylgeranyl transferase inhibitor mimicked the effects of statins. Statins inhibited the membrane translocations of Ras, RhoA, Rac, and Cdc42, and overexpression of dominant-negative mutants of RhoA (DN-RhoA) and Cdc42 (DN-Cdc42), but not of Ras or Rac, increased PPAR
activity. Statins induced extracellular signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK) activation. However, DN-RhoA and DN-Cdc42 activated p38 MAPK, but not ERK1/2. ERK1/2- or p38 MAPKspecific inhibitors abrogated statin-induced PPAR
activation. Statins induced cyclooxygenase (COX)-2 expression and increased intracellular 15-deoxy-
12,14-prostaglandin J2 (15d-PGJ2) levels through ERK1/2- and p38 MAPKdependent pathways, and inhibitors or small interfering RNA of COX-2 inhibited statin-induced PPAR
activation. Statins also activate PPAR
via COX-2dependent increases in 15d-PGJ2 levels. We further demonstrated that statins inhibited lipopolysaccharide-induced tumor necrosis factor
or monocyte chemoattractant protein-1 mRNA expression, and these effects by statins were abrogated by the PPAR
antagonist T0070907 or by small interfering RNA of PPAR
or PPAR
. Statins also induced ATP-binding cassette protein A1 or CD36 mRNA expression, and these effects were suppressed by small interfering RNAs of PPAR
or PPAR
. In conclusion, statins induce COX-2dependent increase in 15d-PGJ2 level through a RhoA- and Cdc42-dependent p38 MAPK pathway and a RhoA- and Cdc42-independent ERK1/2 pathway, thereby activating PPAR
. Statins also activate PPAR
via COX-2dependent pathway. These effects of statins may explain their antiatherogenic actions.
Key Words: cyclooxygenase MAPK macrophages PPAR statins
Related Article:
Circ. Res. 2007 100: 1394-1395.
This article has been cited by other articles:
![]() |
A. Amoruso, C. Bardelli, L. G. Fresu, A. Palma, M. Vidali, V. Ferrero, F. Ribichini, C. Vassanelli, and S. Brunelleschi Enhanced Peroxisome Proliferator-Activated Receptor-{gamma} Expression in Monocyte/Macrophages from Coronary Artery Disease Patients and Possible Gender Differences J. Pharmacol. Exp. Ther., November 1, 2009; 331(2): 531 - 538. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Bujold, D. Rhainds, C. Jossart, M. Febbraio, S. Marleau, and H. Ong CD36-mediated cholesterol efflux is associated with PPAR{gamma} activation via a MAPK-dependent COX-2 pathway in macrophages Cardiovasc Res, August 1, 2009; 83(3): 457 - 464. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Ramji Growth hormone-releasing peptides, CD36, and stimulation of cholesterol efflux: cyclooxygenase-2 is the link Cardiovasc Res, August 1, 2009; 83(3): 419 - 420. [Full Text] [PDF] |
||||
![]() |
C. Nacci, M. Tarquinio, L. De Benedictis, A. Mauro, A. Zigrino, M. R. Carratu, M. J. Quon, and M. Montagnani Endothelial Dysfunction in Mice with Streptozotocin-induced Type 1 Diabetes Is Opposed by Compensatory Overexpression of Cyclooxygenase-2 in the Vasculature Endocrinology, February 1, 2009; 150(2): 849 - 861. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zampetaki and Q. Xu Vascular Remodeling in Diabetes: Don't Leave Without Your STAT5 Arterioscler Thromb Vasc Biol, January 1, 2009; 29(1): 10 - 11. [Full Text] [PDF] |
||||
![]() |
S. Han, X. Sun, J. D. Ritzenthaler, and J. Roman Fish Oil Inhibits Human Lung Carcinoma Cell Growth by Suppressing Integrin-Linked Kinase Mol. Cancer Res., January 1, 2009; 7(1): 108 - 117. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Sun, J. D. Ritzenthaler, Y. Zheng, J. Roman, and S. Han Rosiglitazone inhibits {alpha}4 nicotinic acetylcholine receptor expression in human lung carcinoma cells through peroxisome proliferator-activated receptor {gamma}-independent signals Mol. Cancer Ther., January 1, 2009; 8(1): 110 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Paul, H. H. D. Meyer, K. Leidl, S. Soumian, and C. Albrecht A novel enzyme immunoassay specific for ABCA1 protein quantification in human tissues and cells J. Lipid Res., October 1, 2008; 49(10): 2259 - 2267. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. P. Sundararaj, D. J. Samuvel, Y. Li, A. Nareika, E. H. Slate, J. J. Sanders, M. F. Lopes-Virella, and Y. Huang Simvastatin suppresses LPS-induced MMP-1 expression in U937 mononuclear cells by inhibiting protein isoprenylation-mediated ERK activation J. Leukoc. Biol., October 1, 2008; 84(4): 1120 - 1129. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. R. Chen, V. C. Besson, T. Beziaud, M. Plotkine, and C. Marchand-Leroux Combination Therapy with Fenofibrate, a Peroxisome Proliferator-Activated Receptor {alpha} Agonist, and Simvastatin, a 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitor, on Experimental Traumatic Brain Injury J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 966 - 974. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Taketa, T. Matsumura, M. Yano, N. Ishii, T. Senokuchi, H. Motoshima, Y. Murata, S. Kim-Mitsuyama, T. Kawada, H. Itabe, et al. Oxidized Low Density Lipoprotein Activates Peroxisome Proliferator-activated Receptor-{alpha} (PPAR{alpha}) and PPAR{gamma} through MAPK-dependent COX-2 Expression in Macrophages J. Biol. Chem., April 11, 2008; 283(15): 9852 - 9862. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kourimate, C. Le May, C. Langhi, A. L. Jarnoux, K. Ouguerram, Y. Zair, P. Nguyen, M. Krempf, B. Cariou, and P. Costet Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9 J. Biol. Chem., April 11, 2008; 283(15): 9666 - 9673. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Erdmann Review: Statin plus thiazolidinedione use in patients with diabetes at high cardiovascular risk The British Journal of Diabetes & Vascular Disease, September 1, 2007; 7(5): 211 - 216. [Abstract] [PDF] |
||||
![]() |
R. Paumelle and B. Staels Peroxisome Proliferator-Activated Receptors Mediate Pleiotropic Actions of Statins Circ. Res., May 25, 2007; 100(10): 1394 - 1395. [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |